里昂：升康龙化成目标价至 28.8 港元 维持 “跑赢大市” 评级
Citi released a research report stating that Pharmaron (03759) has raised its revenue growth guidance for 2025 from a year-on-year increase of 10% to 15% to 12% to 16%, and expects adjusted net profit under International Financial Reporting Standards to achieve double-digit growth. The bank believes that the upward guidance and increased order backlog for Pharmaron from the end of this year to next year are encouraging. Citi has raised its revenue and net profit forecasts for Pharmaron for 2025 to 2027, with the target price for H shares increased from HKD 24.7 to HKD 28.8, and the target price for A shares raised from RMB 34.8 to RMB 40.6, maintaining an "Outperform" rating
According to the Zhitong Finance APP, Credit Lyonnais released a research report stating that Pharmaron (03759, 300759.SZ) has raised its revenue growth guidance for 2025 from a year-on-year increase of 10% to 15% to 12% to 16%, and expects adjusted net profit under non-International Financial Reporting Standards to achieve double-digit growth. The bank believes that Pharmaron's upward guidance and increased order backlog are encouraging for the end of this year and into next year. Credit Lyonnais has raised its revenue and net profit forecasts for Pharmaron for 2025 to 2027, with the target price for H-shares increased from HKD 24.7 to HKD 28.8, and the target price for A-shares raised from RMB 34.8 to RMB 40.6, maintaining an "outperform" rating
